New developments on thromboxane modulators.
Thromboxane A(2) (TXA(2)) is a labile product formed from arachidonic acid by cyclooxygenase. The pathogenesis of numerous cardiovascular, pulmonary, and thromboembolic diseases can be related to this metabolite. Therefore, TXA(2) modulators have been developed for 20 years. This review will highlight the evolution in the field of TXA(2) modulators.
Natural and Synthetic Drug Research Centre, Medicinal Chemistry, University of Liège, 1, av. de l'Hôpital, B-4000 Liège, Belgium. Jean-Michel.Dogne@ulg.ac.be
Jean-Michel
JM
Dogné
Julien
J
Hanson
Xavier
X
de Leval
Bernard
B
Masereel
Philippe
P
Kolh
Bernard
B
Pirotte
D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D017482:Receptors, Thromboxane / Q000819:agonists / Q000037:antagonists & inhibitors* / Q000737:chemistry; D015398:Signal Transduction; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D017482:Receptors, Thromboxane; D013928:Thromboxane A2; D013930:Thromboxane-A Synthase